Research on substances with activity against orthopoxviruses

Annals of Agricultural and Environmental Medicine

Volumn 20, Issue 1, 2013, Pages 1-7

  Kolodziej, Marcin ^a   Joniec, Justyna ^a   Bartoszcze, Michal ^a   Gryko, Romuald ^a   Kocik, Janusz ^a   Knap, Józef ^b  

^a MILITARY INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Antivirals; Orthopoxvirus; Smallpox

Indexed keywords

3 DEAZAADENOSINE; 3 DEAZANEPLANOCIN A; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACICLOVIR; ADEFOVIR; CIDOFOVIR; COMPLEMENT INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; IMIQUIMOD; IMMUNOMODULATING AGENT; METISAZONE; NIGERICIN; NUCLEOSIDE DERIVATIVE; PENCICLOVIR; PEPTIDE APTAMER; PEPTIDE DERIVATIVE; PHOSPHOLIPID DERIVATIVE; PLACEBO; PYRAZOLONE DERIVATIVE; PYRIMIDINE DERIVATIVE; RIBAVIRIN; TECOVIRIMAT; TENOFOVIR; THIOSEMICARBAZONE DERIVATIVE; TIAZOFURIN; UNINDEXED DRUG; VANDETANIB;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; C6L GENE; CLINICAL TRIAL (TOPIC); COMPLEMENT SYSTEM; CONDYLOMA ACUMINATUM; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG PENETRATION; DRUG RESEARCH; E3L GENE; EPIDEMIC; HUMAN; IN VITRO STUDY; IN VIVO STUDY; K3L GENE; NONHUMAN; ORTHOPOXVIRUS; POXVIRUS INFECTION; PROGENY; PROTEIN SYNTHESIS INHIBITION; REVIEW; SINGLE DRUG DOSE; SKIN CANCER; SKIN INFECTION; SMALLPOX; VIRION; VIRUS GENE; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; HUMANS; ORTHOPOXVIRUS; POXVIRIDAE INFECTIONS;

ORTHOPOXVIRUS; VARIOLA VIRUS;

EID: 84875586762     PISSN: 12321966     EISSN: 18982263     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Niemiałtowski M, Szulc L, Boratyńska A, Martyniszyn L, Struzik J, Karandys J. Ospa prawdziwa: patrza{ogonek}c wstecz od Edwarda Jennera, a nawet troche{ogonek} dalej (Smallpox: looking back to Edward Jenner and even a little further). Post Mikrob. 2009; 48(4): 289-298 (in Polis).
2. Duraffour S, Meyer H, Andrei G, Snoeck R. Camelpox virus. Antivir Res. 2011; 92(2): 167-186.
3. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, et al. Smallpox as a biological weapon. JAMA. 1999; 281: 2127-2137.
4. Johnson RF, Yellayi S, Cann JA, Johnson A, Smith AL, Paragas J, et al. Cowpox virus infection of cynomolgus macaques as a model of hemorrhagic smallpox. Virology. 2011; 418: 102-112.
5. Baker RO, Bray M, Huggins JW. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antivir Res. 2003; 57: 13-23.
6. Fan X, Zhang X, Zhou L, Keith KA, Kern ER, Torrence PF. A pyrimidine-pyrazolone nucleoside chimer with potent in vitro anti-orthopoxvirus activity. Bioorg Med Chem Lett. 2006; 16: 3224-3228.
7. Painter GR, Hostetler KY. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol. 2004; 22(8): 423-427.
8. Fenner F, Henderson DA, Arita I, Ježek, Ladnyi ID. Smallpox in non-endemic countries. In: Fenner F, Henderson DA, Arita I, Ježek, Ladnyi ID. Smallpox and its eradication. WHO, Geneva 1988.p.1069-1101.
9. Myskiw C, Piper J, Huzarewich R, Booth TF, Cao J, He R. Nigericin is potent inhibitor of the early stage of vaccinia replication. Antivir Res. 2010; 88: 304-310.
10. Aquino LL, Wu JJ. Cutaneous manifestations of category A bioweapons. J Am Acad Dermatol. 2011; 65(6): 1213.e1-1213.e15.
11. Joniec J, Kolodziej M, Bartoszcze M, Kocik J, Knap J. Research on prevention and treatment of hemorrhagic fevers. Ann Agr Env Med. 2012; 19(2): 165-171.
12. Saccucci L, Crance J-M, Colas P, Bickle M, Garin D, Iseni F. Inhibition of vaccinia virus replication by peptide aptamers. Antivir Res. 2009; 82: 134-140.
13. Becker MN, Obraztsova M, Kern ER, Quenelle DC, Keith KA, Prichard MN, et al. Isolation and characterization of cidofovir resistant vaccinia viruses. Virol J. 2008; 5(58).
14. De Clercq E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol Sci. 2002; 23(10): 456-458.
15. Smee DF, Bailey KW, Wong M-H, Sidwell RW. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antivir Res. 2001; 52: 55-62.
16. Smee DF, Wong M-H, Bailey KW, Beadle JR, Hostetler KY, Sidwell RW. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int J Antimicrob Ag. 2004; 23: 430-437.
17. Keith KA, Hitchcock MJM, Lee WA, Holý A, Kern ER. Evaluation of Nucleoside Phosphonates and Their Analogs and Prodrugs for Inhibition of Orthopoxvirus Replication. Antimicrob Agents Ch. 2003; 47(7): 2193-2198.
18. Sauberei A, Meier C, Meerbach A, Schiel M, Helbig B, Wutzler P. In vitro activity od cycloSal-nucleoside monophosphates and polyhydroxy carboxylates against othopoxvirus. Antivir Res. 2005; 67: 147-154.
19. Kane EM, Shuman S. Adenosine N1-Oxide Inhibits Vaccinia Virus Replication by blocking Translation of Viral Early mRNAs. J Virol. 1995; 69(10): 6352-6358.
20. Khandazhinskaya AL, Shirokova EA, Shipitsin AV, Karpenko IL, Belanov EF, Kukhanova MK et al. Adenosine N1-Oxide Analogues as Inhibitors of Orthopox Virus Replication Collect Czech Chem C. 2006; 71(7); 1107-1121.
21. Smee DF, Hurst BL, Wong M-H, Glazer RI, Rahman A, Sidewell RW. Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus. Antivir Res. 2007; 76: 124-129.
22. Chu CK, Jin YH, Baker RO, Huggins J. Antiviral Activity od Cyclopentenyl Nucleosides Against Orthopox Viruses (Smallpox, Monkeypox and Cowpox). Bioorg Med Chem Lett. 2003; 13: 9-12.
23. Yang H, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, et al. An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects from Lethal Orthopoxvirus Challenge. J Virol. 2005; 79(20): 13139-13149.
24. Quenelle DC, Buller RML, Parker S, Keith KA, Hruby DE, Jordan R, et al. Efficacy of Delayed Treatment with ST-246 Given Orally against Systemic Orthopoxvirus infections in Mice. Antimicrob Agents Ch. 2007; 51(2): 689-695.
25. Huggins J, Goff A, Eric M, Twenhafel N, Chapman J, Tate M, et al. Successful Treatment in the Monkeypox and Variola Primate Models of Smallpox by the Oral Drug ST-246. Antivir Res. 2007; 74: A1-A74(A35).
26. Silvermann JEY, Ciustea M, Shudofsky AMD, Bender F, Shoemaker RH, Ricciardi RP. Identification of polymerase and processivity inhibitors of vaccinia DNA synthesis using a stepwise screening approach. Antivir Res. 2008; 80: 114-123.
27. Dower K, Filone CM, Hodges EN, Bjornson ZB, Rubins KH, Brown LE, et al. Identification of pyridopyrimidinone inhibitor of orthopoxviruses from a diversity-oriented synthesis library. J Virol. 2012; 86(5): 2632-2640.
28. Bauer DJ, St Vincent L, Kempe CH, Downie AW. Prophylactic treatment of smallpox contacts with N-metylisatin β-thiosemicarbazone (compound 33t57, marboran). Lancet. 1963; 35: 494-496.
29. Borysiewicz J, Witaliński W. Effect of N,N'-bis(methylisatin-β-thio semicarbazone)-2-methylpiperazine on vaccinia virus replication in vitro and in vivo. Brief report. Antimicrob Agents Ch. 1979; 62(1): 83-86.
30. Woodson B, Joklik WK. The inhibition of vaccinia virus multiplication by isatin-β-thiosemicarbazone. PNAS. 1965; 54(3): 946-953.
31. Neyts J, De Clercq E. Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. Antivir Res. 2003; 57: 25-33.
32. Quenelle DC, Keith KA, Kern ER. In vitro and in vivo evaluation of isatin-β-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. Antivir Res. 2006; 71: 24-30.
33. Prins C, Cresawn SG, Condit RC. An Isatin-β-thiosemicarbazone-resistant vaccinia virus containing a mutation in the second largest subunit of the viral RNA polymerase is defective in transcription elongaction. J Biol Chem. 2004; 279(43): 44858-44871.
34. Prichard MN, Kern ER. Orthopoxvirus Targets for the Development of Antiviral Therapies. Curr Drug Targets - Infections Disorders. 2005; 5: 17-28.
35. Black EP, Condit RC. Phenotypic Characteriszation of mutans in Vaccinia Virus Gene G2R, a Putative Transcription Elongation Factor. J Virol. 1996; 70(1): 47-54.
36. Kolodziej M, Joniec J, Bartoszcze M, Mirski T, Gryko R. Peptydy - nowe możliwości zwalczania zakażeń wirusowych. Przegl Epidemiol. 2011; 65: 477-482.
37. Meyer C, Hahn U, Rentmeister A. Cell-Specific Aptamers as Emerging Therapeutics. J Nucleic Acids. 2011; doi:10.4061/2011/904750.
38. Altmann SE, Jones JC, Schultz-Cherry S, Brandt CR. Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide. Virology. 2009; 388: 248-259.
39. Tarbet EB, Larson D, Anderson BJ, Bailey KW, Wong M-H, Smee DF. Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice. Antivir Res. 2011; 90: 126-133.
40. Perino J, Crouzier D, Spehner D, Debouzy J-C, Garin D, Crance J-M, et al. Lung surfactant DPPG phospholipid inhibits vaccinia virus infection. Antivir Res. 2011; 89: 89-97.
41. Deptała A, Soborczyk A, Krajewska K. Leczenie interferuja{ogonek}ce z funkcja{ogonek} receptora dla naskórkowego czynnika wzrostu (EGFR) u chorych na raka gruczołu krokowego (The treatment interfering with EGFR in prostate cancer patients). Onkol Prak Klin. 2011; 7(4): 208-214 (in Polish).
42. Wcisło G, Szczylik C. Szlak sygnałowy receptora naskórkowego czynnika wzrostu (EGFR) i potencjalne zastosowanie kliniczne jego blokowania w raku nerki (Inhibition of molecular signaling of epidermal growth factor receptor (EGFR) and its clinical potential for treating renal cell cancer). Onkol Prak Klin. 2011; 7(4): 197-207.
43. Langhammer S, Koban R, Yue C, Ellerbrok H. Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa). Antivir Res. 2011; 89: 64-70.
44. Brandt TA, Jacobs BL. Both Carboxy-and Amino-Terminal Domains of the Vaccinia Virus Interferon Resistance Gene, E3L, Are Required for Pathogenesis in a Mouse Model. J Virol. 2001; 75(2): 850-856.
45. Kwon J-A, Rich A. Biological function of the vaccinia virus Z-DNA-binding protein E3L: Gene transactivation and antiapoptotic activity in HeLa cells. PNAS. 2005; 102(36): 12759-12764.
46. Rice AD, Turner PC, Embury JE, Moldawer LL, Baker HV, Moyer RW. Roles of Vaccinia Virus Gene E3L and K3L and Host Genes PKR and RNase L during Intratracheal Infection of C57BL/6 Mice. J Virol. 2011; 85(1): 550-567.
47. Dave RS, McGettigan JP, Quereshi T, Schnell MJ, Nunnari G, Pomerantz RJ. siRNA targeting Vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects. Virology. 2006; 348: 489-497.
48. Li W-X, Li H, Lu R, Li F, Dus M, Atkinson P, et al. Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. PNAS. 2004; 101(5): 1350-1355.
49. Lantermann M, Schwantes A, Sliva K, Sutter G, Schnierle BS. Vaccinia virus double-stranded RNA-binding protein E3 does not interfere with siRNA-mediated gene silencing in mammalian cells. Virus Res. 2007; 126: 1-8.
50. Unterholzner L, Sumner RP, Baran M, Ren H, Mansur DS, Bourke NM, et al. Vaccinia Virus Protein C6 Is a Virulence Factor that Binds TBK-1 Adaptor Proteins and Inhibits Activation of IRF3 and IRF7. PLoS Pathog. 2011; 7(9): e1002247. doi:10.1371/journal.ppat.1002247.
51. Rosengard AM, Liu Y, Nie Z, Jimenez R. Variola virus immune evasion design: Expression of a highly efficient inhibitor of human complement. PNAS. 2002; 99(13): 8808-8813.
52. Liszewski MK, Leung MK, Hauhart R, Mark R, Buller L, Bertram P, et al. Structure and Regulatory Profile of the Monkeypox Inhibitor of Complement: Comparison to Homologs in Vaccinia and Variola and Evidence for Dimer Formation. J Immunol. 2006; 176(6): 3725-3734.
53. Liszewski MK, Leung MK, Hauhart R, Fang CJ, Bertram P, Atkinson JP. Smallpox Inhibitor of Complement Enzymes (SPICE): Dissecting Functional Sites and Abrogating Activity. J Immunol. 2009; 183(5): 3150-3159.